Efficacy and safety of programmed death receptor 1 inhibitor combined with anlotinib in treatment of non-small cell lung cancer

Authors
Category Primary study
JournalCancer Res. Clin.
Year 2025
This article has no abstract
Epistemonikos ID: 4dfa4c8a240f2d2276c7ce9f1053e7ef984fd101
First added on: Aug 02, 2025